GWAS study found the chronic inflammation-associated gene C5 to be in linkage disequilibrium with RA-associated SNPs [64] and a second-generation monoclonal antibody drug against C5, Ravulizumab, has now been approved [65]. This evidence concerns the gene C5 and rheumatoid arthritis.